Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction
Executive Summary
The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.
You may also be interested in...
Amgen VP Encouraged By Initial Clinical Trial Diversity Efforts
Ponda Motsepe-Ditshego, who leads Amgen’s clinical trial diversity efforts, admits they are in early stages but noted progress internally and externally at better representing diverse patient groups.
Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.
Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.